Remicade comes through again for Mitsubishi Tanabe
This article was originally published in Scrip
Executive Summary
Japan's Mitsubishi Tanabe Pharma(MTP) saw its net sales of pharmaceuticals rise by 3% to ¥100.6 billion ($935.6 million) in the first quarter to June 30th, mostly on the back of continued strong growth for Remicade (infliximab) in rheumatoid arthritis.